Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | 2026-02-18 03:41:06 | 2.61 | -0.01 | -0.38 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IOVA | 0001425205 | IOVANCE BIOTHERAPEUTICS, INC. | US4622601007 | 2549002L8WT2ACU5Q878 | 753254381 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 825 INDUSTRIAL ROAD | SAN CARLOS | CA | 94070 | UNITED STATES | US | 6502607120 | 825 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070 | 825 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070 | Lion Biotechnologies, Inc. | Biotechnology | 2007 | — | 319 | http://iovance.com | 2,100,000,000 | 385,461,728 | 396,967,970 | Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer. | 2026-02-12 17:59:15 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 2,100,000,000 | 700,000,000 | 50 | 327,876,694 | 48,569,651 | 17.3893 |
| 2023 | 1,400,000,000 | -200,000,000 | -12.5 | 279,307,043 | 55,068,161 | 24.5578 |
| 2022 | 1,600,000,000 | -2,200,000,000 | -57.8947 | 224,238,882 | 67,070,561 | 42.6744 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Jean-Marc Bellemin | Chief Financial Officer | 2024 | 551,238 | 0 | 2,557,873 | 124,029 | 14,800 | 3,247,940 |
| Igor Bilinsky, Ph.D. | Chief Operating Officer | 2024 | 551,238 | 0 | 2,557,873 | 124,029 | 14,800 | 3,247,940 |
| Frederick G. Vogt | President, Chief Executive Officer, General Counsel | 2024 | 730,060 | 0 | 9,969,063 | 237,270 | 16,800 | 10,953,193 |
| Friedrich Graf Finckenstein, M.D. | Chief Medical Officer | 2024 | 612,109 | 0 | 2,557,873 | 137,725 | 14,800 | 3,322,507 |
| Igor Bilinsky, Ph.D. | Chief Operating Officer | 2023 | 527,500 | 47,475 | 300,393 | 284,850 | 13,200 | 1,591,571 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 838 |
| 2023 | 557 |
| 2022 | 503 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 164,070,000 | 1,189,000 | — |
| Cost Of Revenue | 123,995,000 | 10,755,000 | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 282,336,000 | 344,077,000 | 294,781,000 |
| General And Administrative Expenses | 153,017,000 | 106,916,000 | 104,097,000 |
| Operating Expenses | 559,348,000 | 461,748,000 | 398,878,000 |
| Operating Income | -395,278,000 | -460,559,000 | -398,878,000 |
| Net Income | -372,177,000 | -444,037,000 | -395,893,000 |
| Earnings Per Share Basic | -1.28 | -1.89 | -2.49 |
| Earnings Per Share Diluted | -1.28 | -1.89 | -2.49 |
| Weighted Average Shares Outstanding Basic | 289,877 | 235,131 | 159,259 |
| Weighted Average Shares Outstanding Diluted | 289,877 | 235,131 | 159,259 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 115,694,000 | 114,888,000 | 231,731,000 |
| Marketable Securities Current | 208,087,000 | 164,979,000 | 240,114,000 |
| Accounts Receivable | 69,340,000 | 151,000 | — |
| Inventories | 51,520,000 | 10,372,000 | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 457,018,000 | 307,848,000 | 479,116,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 109,081,000 | 114,030,000 | 105,232,000 |
| Other Assets Non Current | 369,000 | 270,000 | 189,000 |
| Total Assets Non Current | 453,408,000 | 472,503,000 | 184,866,000 |
| Total Assets | 910,426,000 | 780,351,000 | 663,982,000 |
| Accounts Payable | 27,509,000 | 33,123,000 | 26,603,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 81,936,000 | 69,406,000 | 52,295,000 |
| Total Liabilities Current | 122,341,000 | 110,306,000 | 91,485,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 77,680,000 | 85,432,000 | 72,859,000 |
| Total Liabilities | 200,021,000 | 195,738,000 | 164,344,000 |
| Common Stock | 13,000 | 11,000 | 8,000 |
| Retained Earnings | -2,384,552,000 | -2,012,375,000 | -1,568,338,000 |
| Accumulated Other Comprehensive Income | -1,046,000 | 2,526,000 | -902,000 |
| Total Shareholders Equity | 710,405,000 | 584,613,000 | 499,638,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 11,967,000 | 11,568,000 | 9,310,000 |
| Share Based Compensation Expense | 109,627,000 | 62,625,000 | 84,022,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 69,189,000 | 149,000 | — |
| Change In Inventories | 39,917,000 | 10,118,000 | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -7,841,000 | 4,828,000 | 5,883,000 |
| Change In Other Liabilities | 8,578,000 | 19,774,000 | -4,703,000 |
| Cash From Operating Activities | -352,977,000 | -361,820,000 | -292,757,000 |
| Purchases Of Marketable Securities | 460,769,000 | 205,902,000 | 245,816,000 |
| Sales Of Marketable Securities | 428,000,000 | 285,583,000 | 522,696,000 |
| Acquisition Of Property Plant And Equipment | 11,069,000 | 22,290,000 | 20,425,000 |
| Acquisition Of Business | — | 212,633,000 | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -96,411,000 | -155,242,000 | 256,455,000 |
| Tax Withholding For Share Based Compensation | 12,858,000 | 2,795,000 | 2,649,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 397,304,000 | 463,281,000 | 189,502,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 390,664,000 | 462,959,000 | 190,150,000 |
| Change In Cash | -59,265,000 | -56,843,000 | 153,848,000 |
| Cash At End Of Period | 115,694,000 | 114,888,000 | 231,731,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -1.28 | -1.89 | -2.49 |
| Price To Earnings Ratio | -5.7812 | -4.3016 | -2.5663 |
| Earnings Growth Rate | -32.2751 | -24.0964 | 11.6592 |
| Price Earnings To Growth Ratio | 0.1791 | 0.1785 | -0.2201 |
| Book Value Per Share | 2,450.7119 | 2,486.3289 | 3,137.267 |
| Price To Book Ratio | 0.003 | 0.0033 | 0.002 |
| Ebitda | -360,210,000 | -432,469,000 | -386,583,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 7,018,000 | 20,366,000 | 13,604,000 |
| Free Cash Flow | -359,995,000 | -382,186,000 | -306,361,000 |
| Return On Equity | -0.5239 | -0.7595 | -0.7924 |
| One Year Beta | 2.057 | 1.431 | 1.3568 |
| Three Year Beta | 1.4936 | 1.41 | 1.26 |
| Five Year Beta | 1.3292 | 1.3092 | 1.3301 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Kirby Daniel Gordon | Chief Commercial Officer | 2026-02-10 | 39,996 | A | 69,996 |
| Kirby Daniel Gordon | Chief Commercial Officer | 2026-02-10 | 16,450 | D | 53,546 |
| Kirby Daniel Gordon | Chief Commercial Officer | 2026-02-10 | 39,996 | D | 80,004 |
| Vogt Frederick G | Director, Interim CEO & General Counsel | 2025-12-02 | 10,417 | A | 468,948 |
| Vogt Frederick G | Director, Interim CEO & General Counsel | 2025-12-02 | 4,426 | D | 464,522 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Cetera Investment Advisers | 2025-12-31 | 192,940 | 70,674 | 2.73 |
| AQR CAPITAL MANAGEMENT LLC | 2025-12-31 | 301,913 | 110,591 | 2.73 |
| Palo Alto Investors LP | 2025-12-31 | 19,428,525 | 7,116,676 | 2.73 |
| CIM INVESTMENT MANAGEMENT INC | 2025-12-31 | 80,325 | 29,423 | 2.73 |
| Jain Global LLC | 2025-12-31 | 852,022 | 312,096 | 2.73 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-11-30 | SIIT Extended Market Index Fund - Class A | SMXAX | 38,300 | 94,601 | 0.0078 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-11-30 | SIIT Multi-Asset Real Return Fund - Class A | SEIAX | 2,165 | 5,347.55 | 0.0007 |
| Invesco Exchange-Traded Fund Trust II | 2025-11-30 | Invesco Nasdaq Biotechnology ETF | IBBQ | 16,942 | 41,846.74 | 0.0704 |
| Invesco Exchange-Traded Fund Trust II | 2025-11-30 | Invesco NASDAQ Future Gen 200 ETF | QQQS | 24,146 | 59,640.62 | 0.4901 |
| PROSHARES TRUST | 2025-11-30 | ProShares Ultra Nasdaq Biotechnology | BIB | 16,899 | 41,740.53 | 0.0476 |